Infilea (Clobetasol Propionate)

Clobetasol propionate binds to glucocorticoid receptors inside skin cells, altering gene expression to suppress the production of inflammatory cytokines and chemokines. This reduces immune cell infiltration, edema and keratinocyte proliferation, providing a rapid anti‑inflammatory and immunosuppressive effect on the skin.

The specific dose and frequency of Infilea are determined by the prescribing clinician based on the severity of the skin condition, the area to be treated and patient factors. Patients should follow the healthcare professional’s instructions and not exceed the recommended amount.

Safety data for clobetasol propionate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Infilea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Infilea (clobetasol propionate) is classified as a super‑potent (class I) corticosteroid, offering stronger anti‑inflammatory activity than mid‑potency agents such as betamethasone or mometasone. It is typically reserved for severe or resistant dermatoses where lower‑potency steroids have been ineffective.

Store Infilea at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and potency.

Infilea is applied topically to clean, dry skin. A thin layer should be spread over the affected area, gently massaged in, and washed off after the prescribed period if instructed. Occlusive dressings should be avoided unless directed by a clinician.

Serious risks include skin atrophy, telangiectasia, hypopigmentation and, with extensive use, systemic adrenal suppression. Patients should report signs of severe thinning, bruising, unexplained fatigue or hormonal disturbances to their healthcare provider promptly.

Infilea should not be used on untreated bacterial, fungal or viral skin infections, on large surface areas for prolonged periods, or in individuals with known hypersensitivity to clobetasol propionate or any formulation excipients. Children under two years of age require special caution and medical supervision.